Yi-Wei Merges with Jianya; Lin Han-fei: If Major Shareholder Exercises Dissenting Rights, Shares Will Be Bought Back According to Law

Central News Agency (CNA) -- (Reporter He Xiu-ling, Taipei, April 16) Yi-Wei Bio-medical Chairman Lin Han-fei stated that if the share swap between Yi-Wei and Jianya is approved and Jianya's major shareholder Johnson exercises dissenting rights to demand the repurchase of its shares, Yi-Wei will buy back the relevant shares according to law. Yi-Wei held an investor conference today. In March this year, Jianya and Yi-Wei's boards of directors resolved to approve the share conversion, making Jianya a wholly-owned subsidiary of Yi-Wei and applying for delisting; however, Johnson continued to buy Jianya shares and increase its investment last year. Johnson stated in March this year that it questioned the financial stability of this merger and did not rule out exercising its share purchase request rights; on the 15th, it issued another statement saying that this case would severely devalue Jianya's corporate value. Currently, it holds 27.05% of Jianya's shares and has gained shareholder support, which, when added to supporting shares, will approach 40%, potentially blocking this share swap merger. Jianya will hold a shareholders' meeting on April 22nd. Johnson pointed out that according to Article 18 of the Business Mergers and Acquisitions Act, if the share swap merger does not achieve the attendance of more than 2/3 of Jianya's total shares, and over half of the attending shareholders' shares approve, the proposal will not pass. After the investor conference, Lin Han-fei stated that if the merger with Jianya is approved and Johnson further exercises dissenting rights to demand the company buy back its shares, Yi-Wei will handle the shares held before the stock transfer registration cut-off date of the shareholders' meeting according to procedures, and the repurchase price will be determined through negotiation or by the court. Lin Han-fei reiterated that the share swap merger with Jianya is a "consensual alliance" based on high complementarity and focusing on long-term value; both parties will integrate their R&D, manufacturing, and sales channel advantages to create an integrated cross-regional platform, which not only echoes the government's policy to strengthen the pharmaceutical industry chain but also significantly enhances the merged entity's market size, revenue, and competitiveness. (Editor: Zhang Liang-zhi) 1150416 Stand with the facts. Your sponsorship is the power to protect news freedom. Download the CNA "One-Stop News" APP for the latest news. Text, images, and videos on this website may not be reproduced, publicly broadcast, transmitted, or used without authorization.